• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights of People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Development
      • AB Science – Masitinib
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Radicava/Edaravone
      • Neudexta
      • Riluzole/Tiglutik
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Innovation Award Nomination
      • Forbes Norris Award Nomination
      • Humanitarian Award Nomination
      • Allied Health Professional Award Nomination
  • Members
    • Member Registration
    • Forgot Password

Mitsubishi Tanabe Pharma America – Oral Edaravone

Mitsubishi Tanabe Pharma America – oral edaravone

Background

Mitsubishi Tanabe Pharma America (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), founded in Japan in 1678. MTPC began studying an intravenous (IV) formulation (Radicava) of edaravone for ALS in 2001 and was approved for the treatment of ALS in Japan and South Korea in 2015, with subsequent approvals in Canada, Switzerland, China, Indonesia and Thailand.

Treatment with Radicava follows a regimen of initial treatment daily for 14 days, followed by a 14-day drug free period, and subsequent cycles of daily dosing for 10 of 14 days, followed by a 14-day drug free period.

During clinical development of IV Radicava, MTPA began a series of steps to determine if an oral suspension of edaravone could add to or replace the IV formulation for treatment of people living with ALS. First, bioequivalence had to be established to demonstrate that the oral edaravone could provide identical exposure as the established IV formulation. Multiple studies were performed.

The process began with a phase 1, open-label, single-dose crossover study in 42 participants, comparing 105 mg oral edaravone with 60 mg/hr IV formulation. Through comparing the pharmacokinetics (how it moves through the body) of both, it was concluded that the two formulations, at their respective doses, demonstrated equivalent exposure. This is published here.

Further, two additional phase 1 studies were performed. First, a placebo-controlled, randomized, single-blind study of increasing oral edaravone doses from 30 to 300 mg in 56 participants was completed. The second study, involving 84 participants, assessed whether oral edaravone interacted with other drugs and also examined potential pharmacokinetic differences between people of different racial backgrounds. In both cases, oral edaravone was considered safe and tolerable with no significant drug interaction effects or differences between racial backgrounds. These studies are published here.

Following bioequivalence, the next step was to undertake a large safety and tolerability trial of oral edaravone at the intended clinical dose. On December 9, 2021, MTPA announced the results of the global phase 3 clinical trial assessing safety and tolerability of oral edaravone over 24 weeks. The study enrolled 185 participants with ALS across 50 sites in the United States, Canada, Europe and Japan and included a long-term safety extension study of up to 96 weeks. No severe treatment emergent adverse events (TEAEs) were reported. It is expected that these results will be used in a regulatory submission for oral edaravone to be considered an equivalent treatment for ALS as Radicava, in the jurisdictions where it is currently approved.

On May 13, 2022, it was announced that the U.S. Food and Drug Administration (FDA) had approved RADICAVA ORS and it became available as of June 16. As of July 2022, edaravone oral suspension is also under review in Japan, Switzerland and Canada.

Simultaneously, MTPA has launched a phase 3b, multi-national, randomized, double-blind study to evaluate daily dosing of oral edaravone as compared to the current IV dosing regimen. Over 48 weeks, 380 participants either received oral edaravone once daily or for 10 days followed by an 18 day placebo suspension. This trial will evaluate a comparison of change in ALSFRS-R as the primary outcome measure and additional outcomes including slow vital capacity, quality of life (ALSAQ-40). It is set to read out in the second half of 2023.

Summary

Based on the available evidence, it is the opinion of the SAC that oral edaravone appears to be safe, tolerable and provides an equivalent drug exposure to intravenous Radicava. For those who currently access Radicava, it may provide a less burdensome alternative if approved.

International Alliance of ALS/MND Associations
August 2022


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

  • Erwin Coppejans, Diagnosed 2007 - ALS Liga België, Belgium

    Erwin Coppejans, Diagnosed 2007 – ALS Liga België, Belgium

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Denis Blais, Diagnosed 2015 - ALS Canada

    Denis Blais, Diagnosed 2015 – ALS Canada

  • Len Johnrose, MND Association, Diagnosed 2017, England

    Len Johnrose, MND Association, Diagnosed 2017, England

  • Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014, Switzerland

    Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014, Switzerland

  • Osiel Mendoza, Diagnosed 2016 - ALS Therapy Development Institute, USA

    Osiel Mendoza, Diagnosed 2016 – ALS Therapy Development Institute, USA

  • Ann Nicol

    Ann Nicol

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • Chen Chun-Chin

    Chen Chun-Chin

  • Joyce Rusinak, Forbes Norris ALS Center, USA

    Joyce Rusinak, Forbes Norris ALS Center, USA

  • Sally Pauls, Diagnosed 2006 - Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 – Les Turner ALS Foundation

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Zabun Nassar, MND Association, Diagnosed 2016, England

    Zabun Nassar, MND Association, Diagnosed 2016, England

  • Inta Grubb, Diagnosed 2014 - MND Australia

    Inta Grubb, Diagnosed 2014 – MND Australia

  • Willi Klein

    Willi Klein

  • Eddy LeFrançois, Diagnosed 1992 - ALS Canada

    Eddy LeFrançois, Diagnosed 1992 – ALS Canada

  • Steven Spencer, Diagnosed 2014 - MND New Zealand

    Steven Spencer, Diagnosed 2014 – MND New Zealand

  • Kirsten Harley, Diagnosed 2013 - Australia

    Kirsten Harley, Diagnosed 2013 – Australia

  • Fabio Carvalho

    Fabio Carvalho

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

  • Joy Blakeley, Diagnosed 2017 - MND Australia

    Joy Blakeley, Diagnosed 2017 – MND Australia

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Philip Brindle, MND Association, Diagnosed 2015, England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • David Watson, MND Scotland, Diagnosed 2018, Scotland

    David Watson, MND Scotland, Diagnosed 2018, Scotland

  • Ian Roberts

    Ian Roberts

  • Charlie “Hark” Dourney, Diagnosed 2007 - Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 – Hark ALS, USA

  • Peng Yi-Wen

    Peng Yi-Wen

  • Roy

    Roy
    roy

  • Jo Knowlton and her dog, Scotland

    Jo Knowlton and her dog, Scotland

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • Frank "Papa" Taylor

    Frank “Papa” Taylor

  • David Bishop

    David Bishop

  • Susan Anderson, Diagnosed 2014 - Hope Loves Company, USA

    Susan Anderson, Diagnosed 2014 – Hope Loves Company, USA

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Marcel R. Wernard, Diagnosed 2016 - ALS Patients Connected, The Netherlands

    Marcel R. Wernard, Diagnosed 2016 – ALS Patients Connected, The Netherlands

  • Juvenal Bayona Romero

    Juvenal Bayona Romero

  • Josée Kolijn-de Man, Diagnosed 2015 - ALS Patients Connected, The Netherlands

    Josée Kolijn-de Man, Diagnosed 2015 – ALS Patients Connected, The Netherlands

  • Richard Clark, MND New Zealand, Diagnosed 2011, New Zealand

    Richard Clark, MND New Zealand, Diagnosed 2011, New Zealand

  • Joanne Pratt, Diagnosed 2011 - MND Australia

    Joanne Pratt, Diagnosed 2011 – MND Australia

  • Oliver Juenke, DGM, Germany

    Oliver Juenke, DGM, Germany

  • Mike Rannie, ALS Canada, Diagnosed 2017, Canada

    Mike Rannie, ALS Canada, Diagnosed 2017, Canada

  • Elkin Ramiro Gaviria Muñoz, Diagnosed  December 2018

    Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

  • Conny van der Meijden, Diagnosed 2001 - ALS Netherlands

    Conny van der Meijden, Diagnosed 2001 – ALS Netherlands

  • Wilfried Leusing, Diagnosed 2010 - DGM, Germany

    Wilfried Leusing, Diagnosed 2010 – DGM, Germany

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2023 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login